Systemic Antifungals Market Size, Share, By Drug Classes (Azoles, Echinocandins, Polyenes, and Others), Indication (Aspergillosis, Histoplasmosis, Gastrointestinal Candidiasis, Blastomycosis, Fungal Endocarditis, and Others), End-Users (Hospital & Specialty Clinics, Ambulatory Surgical Centers, Research Institute & Clinical Trial Centers, and Others), and Region - Trends, Analysis, and Forecast till 2035

• Till 2035, the market is envisioned to flourish at USD 36.8 Billion.
• The systemic antifungals market size was worth USD 11.93 Billion in 2024.
• Target market is increasing in size at a CAGR of 10.9%.

Systemic antifungal are drugs which are used to treat systemic mycoses which are fungal infections affecting internal organs. Systemic antifungals are either fungicidal (kill the fungus) or fungistatic (inhibit fungal growth). The systemic antifungals market is experiencing significant growth due to multiple factors, including rising fungal infections, expansion of ICU and critical care units, rising antifungal resistance and need for new treatments, growing geriatric population and advancements in drug development.

AI Contribution in Membrane Electrode Assembly:

• Artificial Intelligence (AI) is being utilized in the field of systemic antifungals to improve the diagnosis of fungal infections, predict antifungal susceptibility, identify potential new antifungal drug targets, and optimize treatment strategies by analyzing large datasets of patient information and fungal characteristics, allowing for more precise and personalized treatment approaches.

Key Drivers of Target Market:

Rising Number of Patients with Fungal Infections Stimulate Market Growth

The market for systemic antifungals is growing as a direct result of an increase in fungal infections, particularly systemic ones. As more people get these serious fungal infections, there is a greater need for antifungal medications that work to treat the infection. Pharmaceutical companies are thus creating and distributing new systemic antifungal drugs to meet this growing demand, further expanding the systematic antifungals market growth.

• For instance, according to the data published by International Society for Infectious Diseases in September 2024, an annual incidence of 6.5 million invasive fungal infections, associated with approximately 3.8 million mortalities, of which 2.5 million are directly attributable to these infections. Each year, over 2.1 million people develop invasive aspergillosis, with an alarming 85.2% mortality rate. Chronic pulmonary aspergillosis affects 1.84 million people annually, with a significant mortality rate of 18.5%. Pneumocystis pneumonia claims over 214,000 lives annually, impacting 505,000 individuals worldwide, with a significant mortality rate of 42.4%. Annual estimates indicate that 194,000 individuals develop Cryptococcal meningitis, associated with 147,000 fatalities.

Restraints:

Side Effects of Systemic Antifungals can Disturb Market Growth

Systemic antifungal medications can have side effects, including gastrointestinal issues, such as nausea, vomiting, diarrhea, abdominal pain, and others. The skin reactions include itching, burning, rash, peeling skin, and others, liver damage, and so on. They can also interact with other medications, which can increase the risk of toxicity.

• Counterbalance Statements: Solutions to mitigate and manage these side effects effectively are dose adjustment & monitoring, use of liposomal & novel formulations, managing hepatotoxicity (liver toxicity), preventing nephrotoxicity (kidney damage), managing gastrointestinal (gi) side effects, and others.

Opportunities:

New Innovations may Schedule to Lift the Market Growth

Future market expansion will be fuelled by new developments that improve medication efficacy, lower toxicity, and combat antifungal resistance. The creation of liposomal formulations and next-generation antifungals will enhance patient outcomes while reducing adverse effects. Precision medicine and AI-driven drug development will speed up the identification of novel antifungal agents and allow for more individualized treatment plans. Immunotherapies, antifungal vaccinations, and therapeutic drug monitoring (TDM) will also increase the range of preventive and therapeutic choices.

• For instance, in March 2023, the U.S. Food and Drug Administration (FDA) has approved rezafungin for injection, (REZZAYO), a treatment for patients with candidemia and invasive candidiasis. Based on the totality of clinical data generated, rezafungin for injection has the potential to simplify the management of invasive candidiasis and enhance the continuity of antifungal care.

Drug class, indication, end-users, and region are segmentation components of the market.

Drug Class

The market by drug class is segmented into azoles, echinocandins, polyenes, and others. Azoles holds largest systemic antifungal drugs market share as they are the most commonly used drugs for treating systemic fungal infections.

• For instance, in March 2023, the FDA approved Cidara Therapeutics and Melinta Therapeutics’ Rezzayo (rezafungin) injection to treat candidemia and invasive candidiasis. Rezzayo, a once-weekly injection, is the first new echinocandin approved in more than a decade.
• For instance, in April 2022, Drugmaker Dr. Reddy’s Laboratories has introduced Posaconazole Delayed-Release Tablets, 100 mg in the U.S. An azole antifungal, the product is a therapeutic generic equivalent to Noxafil (posaconazole) Delayed-Release Tablets, 100 mg and has been introduced following the U.S. Food and Drug Administration’s approval. It is indicated for prophylaxis of certain fungal infections in severely immunocompromised patients.

Indication

The market through indication is categorized into aspergillosis, histoplasmosis, gastrointestinal candidiasis, blastomycosis, fungal endocarditis, and others. Aspergillosis is superior as compared to other indications. Aspergillosis is a fungal infection that affects many people, especially those with weakened immune systems. As a result, the market is driven by the increasing number of people with aspergillosis.

• For Instance, in September 2023, BDR Pharmaceutical announced the launch of Zisavel capsules for treating invasive aspergillosis and mucormycosis, both fungal infections. BDR Pharmaceuticals aims to make the treatment of invasive fungal diseases with isavuconazole as affordable as voriconazole and posaconazole, two new-generation antifungal agents. This initiative aims to widen access to these crucial medications, ensuring they are within reach of patients who currently struggle to afford them.

End-Users

On the account of end-users, the market is distributed into hospital & specialty clinics, ambulatory surgical centers, research institute & clinical trial centers, and others. However, hospital and specialty clinics influence market expansion as compared to other end-users owing to the increasing prevalence of fungal diseases and expanding healthcare infrastructure.

Regional

Geographically, the market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America: This region dominates the systemic antifungals market with 40.5% share due to several key factors, such as high prevalence of fungal infections, strong pharmaceutical industry and R&D investments, high healthcare spending & favorable reimbursement policies, rise in antifungal resistance, increasing cases of hospital-acquired infections (HAIS), and many others.

• For instance, in December 2023, Astellas Pharma US, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved CRESEMBA, an azole antifungal drug, for the treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients. CRESEMBA for injection is approved for adults and now for pediatric patients 1 year of age and older. CRESEMBA capsules are approved for adults and now for pediatric patients 6 years of age and older who weigh 16 kilograms (kg) and greater.

Asia Pacific: This region holds the second-largest systemic antifungals market share due to several key factors including rising prevalence of fungal infections, increasing incidence of antifungal resistance, expanding healthcare infrastructure, high ICU & ventilator-associated fungal infections, government & private sector investments in research and developments and so forth.

• For instance, Nafithromycin, was officially launched on November 20, 2024, by Union Minister of India. Developed by Wockhardt with support from the Biotechnology Industry Research Assistance Council (BIRAC), Nafithromycin, marketed as "Miqnaf," targets Community-Acquired Bacterial Pneumonia (CABP) caused by drug-resistant bacteria, which disproportionately affects vulnerable populations, such as children, the elderly, and those with compromised immune systems.

Systemic Antifungals Market Report Scope:

Segmentation:

By Drug Class:

• Azoles
• Echinocandins
• Polyenes
• Others

By Indication:

• Aspergillosis
• Histoplasmosis
• Gastrointestinal Candidiasis
• Blastomycosis
• Fungal Endocarditis
• Others

By End Users:

• Hospital & Specialty Clinics
• Ambulatory Surgical Centers
• Research Institute & Clinical Trial Centers
• Others

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • Indonesia
  • Malaysia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Companies actives in systemic antifungals market are GSK plc, AGRIBEGRI.COM, Bayer AG, Merck & Co., Inc., Gilead Sciences, Inc., and among others. These key players are focusing on different organic and inorganic strategies, such as acquisition, merger, partnership, agreement, investment, and others. 

List of Key Players in the Market:

• GSK plc
• Bayer AG
• Merck & Co., Inc.
• Gilead Sciences, Inc.
• Astellas Pharma Inc.
• Enzon Pharmaceuticals, Inc.
• SCYNEXIS, Inc.
• Novartis AG
• Xian Janssen Pharmaceutical Ltd.
• AdvaCare Pharma

• In January 2024, Fresenius Kabi announced that it has introduced Posaconazole Injection, a generic substitute for Noxafil, for use in treating or preventing serious fungal infections in adults and children who have an increased chance of getting these infections due to a weakened immune system. Now available in the U.S., Posaconazole Injection is the newest addition to Fresenius Kabi’s portfolio of more than 30 anti-infective molecules.
• In July 2021, Pharma major Cadila Pharmaceuticals has launched a new triazole antifungal drug Posaconazole, which has been found to be effective against a wide range of invasive fungal disease. The drug has also been recommended as a second line treatment for Mucormycosis or black fungus as it is commonly known.

Analyst View:      

A number of factors, such as an increase in fungal infections, the growth of intensive care units and critical care units, the need for innovative treatments and antifungal resistance, the aging population, and improvements in drug research, are driving the market for systemic antifungals.

More Related Reports

Systemic Lupus Erythematosus Market
Systemic Sclerosis Market
Brand Drugs Market
U.S. Retail Clinics Market
Surgical Stapler Market